Biricodar(Vx-710)|CAS 159997-94-1|DC Chemicals

Cas No.:	159997-94-1
Chemical Name:	Biricodar
Synonyms:	2-Piperidinecarboxylicacid, 1-[2-oxo-2-(3,4,5-trimethoxyphenyl)acetyl]-,4-(3-pyridinyl)-1-[3-(3-pyridinyl)propyl]butyl ester, (2S)-;1,7-Di(3-pyridinyl)-4-heptanyl (2S)-1-[oxo(3,4,5-trimethoxyphenyl )acetyl]-2-piperidinecarboxylate;2-Piperidinecarboxylicacid, 1-[2-oxo-2-(3,4,5-trimethoxyphenyl)acetyl]-,4-(3-pyridinyl)-1-[3-(...;2-Piperidinecarboxylicacid, 1-[2-oxo-2-(3,4,5-trimethoxyphenyl)acetyl]-,4-(3-pyridinyl)-1-[3-(3-pyridinyl)propyl]butyl ester,;4-pyridin-3-yl-1-(3-pyridin-3-ylpropyl)butyl (2S)-1-[oxo(3,4,5-trimethoxyphenyl)acetyl]piperidine-2-carboxylate;VX-710;Biricodar;VX-710(biricodar);Incel;3KG76X4KJK;1,7-dipyridin-3-ylheptan-4-yl (2S)-1-[2-oxo-2-(3,4,5-trimethoxyphenyl)acetyl]piperidine-2-carboxylate;Biricodar [INN];Vx 710;BDBM50109811;DB04851;Q4916332;(S)-1-[2-Oxo-2-(3,4,5-trimethoxy-phenyl)-acetyl]-piperidine-2-carboxylic acid 4-pyridin-3-yl-1-(3-pyridin-3-yl-propyl)-butyl ester;2-Piperidinecarboxylic acid, 1-(oxo(3,4,5-trimethoxyphenyl)acetyl)-
SMILES:	O(C([C@]1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])N1C(C(C1C([H])=C(C(=C(C=1[H])OC([H])([H])[H])OC([H])([H])[H])OC([H])([H])[H])=O)=O)=O)C([H])(C([H])([H])C([H])([H])C([H])([H])C1=C([H])N=C([H])C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])C1=C([H])N=C([H])C([H])=C1[H]
Formula:	C₃₄H₄₁N₃O₇
M.Wt:	603.7052
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

MSDS

Cat. No.	Product name	Field of application
DC31074	Isopropyl myristate	Isopropyl myristate is the ester of isopropyl alcohol and myristic acid.
DC75868	AZ14133346	AZ14133346 (compound 36) is a potent and selective inhibitor of EGFR Exon20 insertions, with the IC50 of 85 nM. AZ14133346 plays an important role in cancer research.
DC75865	TI17	TI17 represents a novel class of targeted anticancer agents that specifically disrupt DNA damage repair mechanisms in malignant cells.
DC75816	Nisoxetine	Nisoxetine acts as a highly selective and potent noradrenaline transporter (NET) antagonist, exhibiting a binding affinity (Kd) of 0.76 nM. In addition to its antidepressant properties, nisoxetine functions as a local anesthetic by inhibiting voltage-gated sodium channels. This dual pharmacological activity makes it a compound of interest for both neurological and pain management research.
DC75641	GENZ-644282 TFA salt	Genz-644282, also known as SAR402674, is a non-camptothecin inhibitor of topoisomerase I with potential antineoplastic activity. Topoisomerase I inhibitor Genz-644282 binds to and inhibits the enzyme topoisomerase I, which may result in the inhibition of repair of single-strand DNA breaks, DNA replication, and tumor cell growth in susceptible tumor cell populations.
DC75325	PSMA-617 TFA	PSMA-617, also know as vipivotide tetraxetan, is a ligand used to make 177Lu-PSMA-617, which is a radioactive molecule to fight cancer. PSMA617 possesses a small peptide, which was designed to target prostate-specific membrane antigen (PSMA). PSMA617 demonstrates high radiolytic stability for at least 72 h. PSMA617 has high inhibition potency (equilibrium dissociation constant Ki=2.34±2.94 nM on LNCaP; Ki=0.37±0.21 nM enzymatically determined). 177 Lu-PSMA-617 offers a potential additional life-prolonging treatment option for men with mCRPC.
DC75202	Fosaprepitant free acid	Fosaprepitant, also known as MK0517, is an antiemetic drug, administered intravenously. It is a prodrug of aprepitant. Fosaprepitant was developed by Merck & Co. and was approved. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment. Fosaprepitant is a weak inhibitor of CYP3A4, and aprepitant, the active moiety, is a substrate, inhibitor, and inducer of CYP3A4
DC74748	O4I4	O4I4 (compound 23) is a OCT4-inducing compound with metabolical stability.
DC74684	ZH8667	ZH8667 is a trace amine-associated receptor 1 (TAAR1)–Gs agonist.
DC74646	EB-PSMA-617	EB-PSMA-617 is an Evans blue-modified prostate-specific membrane antigen (PSMA) 617 ligand for making 177Lu-EB-PSMA, which is potential useful for Metastatic Castration-Resistant Prostate Cancer.